

Edition : SEPTEMBRE 2018



- [1] **“Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [2] **“Establishing a Clinical Laboratory in a Tertiary/Quaternary Care Greenfield Hospital in the Middle East: Recounting the Cleveland Clinic Abu Dhabi Experience,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [3] **“Establishing an Anatomic Pathology Laboratory at Cleveland Clinic Abu Dhabi,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [4] **“Fast Track to Accreditation: An Implementation Review of College of American Pathologists and International Organization for Standardization 15189 Accreditation,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [5] **“Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [6] **“Fibrolamellar Carcinoma: A Concise Review,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [7] **“Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [8] **“Impact of Pathologist Involvement in Sarcoma and Rare Tumor Patient Support Groups on Facebook: A Survey of 542 Patients and Family Members,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [9] **“Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [11] **“One Thousand and One Nights: New Stories of Courage and Passion From the Middle East,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [12] **“Overdiagnosis of Thyroid Cancer: Is This Not an Ethical Issue for Pathologists As Well As Radiologists and Clinicians?,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [13] **“Serous Neoplasms of the Pancreas: A Comprehensive Review,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [14] **“Update on Rare Idiopathic Interstitial Pneumonias and Rare Histologic Patterns,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [15] **“Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.
- [16] **“Utility of Core Needle Biopsies and Transbronchial Biopsies for Diagnosing Nonneoplastic Lung Diseases,”** *Arch. Pathol. Lab. Med.*, Sep. 2018.



- [1] "***BRAF*^{V 600E} mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary,**" *Histopathology*, Sep. 2018.
- [2] "**A subset of so-called dermal non-neural granular cell tumours are underlined by *ALK* fusions, further supporting the idea that they represent a variant of epithelioid fibrous histiocytoma,**" *Histopathology*, Sep. 2018.
- [3] "**Breast cancer metastatic to the liver with hepatoid features and hepatocyte paraffin 1 positivity mimicking hepatocellular carcinoma,**" *Histopathology*, Sep. 2018.
- [4] "**Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR),**" *Histopathology*, Sep. 2018.
- [5] "**Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma,**" *Histopathology*, Sep. 2018.
- [6] "**DNA content analysis of colorectal serrated lesions detects an aneuploid subset of inflammatory bowel disease-associated serrated epithelial change and traditional serrated adenomas,**" *Histopathology*, Sep. 2018.
- [7] "**Eosinophilic oesophagitis: relevance of mast cell infiltration,**" *Histopathology*, Sep. 2018.
- [8] "**GALT carcinoma: three case reports with glycoprotein 2 immunohistochemistry and electron microscopic observations,**" *Histopathology*, Sep. 2018.
- [9] "**High expression of CD10 in anaplastic thyroid carcinomas,**" *Histopathology*, Sep. 2018.
- [10] "**Immunohistochemical and genetic characteristics of a colorectal mucin-rich variant of traditional serrated adenoma,**" *Histopathology*, Sep. 2018.
- [11] "**Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma,**" *Histopathology*, Sep. 2018.
- [12] "**Interobserver reliability of histopathological features for distinguishing between cutaneous polyarteritis nodosa and superficial thrombophlebitis,**" *Histopathology*, Sep. 2018.
- [13] "**Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment,**" *Histopathology*, Sep. 2018.
- [14] "**PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients,**" *Histopathology*, Sep. 2018.
- [15] "**Pentameric last-digit preference and stage border avoidance in pathology measurement,**" *Histopathology*, Sep. 2018.
- [16] "**Peritumoral granulomatous reaction in endometrial carcinoma: association with DNA mismatch repair protein deficiency, particularly loss of PMS2 expression,**" *Histopathology*, Sep. 2018.
- [17] "**PHOX2B is a reliable immunomarker in distinguishing peripheral neuroblastic tumours from CNS embryonal tumours,**" *Histopathology*, Sep. 2018.

- [18] "Significant increases in the density and number of lymphatic vessels in pleuroparenchymal fibroelastosis," *Histopathology*, Sep. 2018.
- [19] "Spindle cell rhabdomyosarcoma of bone with *FUS-TFCP2* fusion: confirmation of a very recently described rhabdomyosarcoma subtype," *Histopathology*, Sep. 2018.
- [20] "Subcentimetre non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)," *Histopathology*, Sep. 2018.

Diagnostic Histopathology

- [1] "Parathyroid adenoma, follicular variant: frozen section reporting," *Diagnostic Histopathol.*, Sep. 2018.
- [2] "Post-mortem imaging in adults," *Diagnostic Histopathol.*, Sep. 2018.
- [3] "Investigating drugs of abuse at autopsy," *Diagnostic Histopathol.*, Sep. 2018.
- [4] "Investigating infectious diseases at autopsy," *Diagnostic Histopathol.*, Sep. 2018.
- [5] "The spectrum of inheritable cardiac disease in sudden cardiac death: investigation and pathology," *Diagnostic Histopathol.*, Sep. 2018.

- [1] **"Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC): A Multiinstitutional Study of 40 Cases With Clinical Follow-up.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [2] **"Challenges in Pathologic Staging of Renal Cell Carcinoma: A Study of Interobserver Variability Among Urologic Pathologists.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [3] **"Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [4] **"Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [5] **"Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [6] **"Cutaneous Non-Neural Granular Cell Tumors Harbor Recurrent ALK Gene Fusions.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [7] **"Cytology Preparations of Formalin Fixative Aid Detection of Giardia in Duodenal Biopsy Samples: A Helpful Tool for Diagnosing Esophageal Candidiasis as Well?,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [8] **"Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [9] **"Frequent GNAQ and GNA14 Mutations in Hepatic Small Vessel Neoplasm.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [10] **"Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [11] **"Molecular Profiling of Hyalinizing Clear Cell Carcinomas Revealed a Subset of Tumors Harboring a Novel EWSR1-CREM Fusion: Report of 3 Cases.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [12] **"Poorly Differentiated Nonkeratinizing Squamous Cell Carcinoma of the Thymus: Clinicopathologic and Molecular Genetic Study of 25 Cases.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [13] **"Pulmonary Carcinomas With Mucinous and Neuroendocrine Differentiation: Expanding the Spectrum of Amphicrine Carcinomas.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [14] **"Pyloric Gland Adenoma (PGA) of the Gallbladder: A Unique and Distinct Tumor from PGAs of the Stomach, Duodenum, and Pancreas.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [15] **"Statement on Best Practices in the Use of Pathology as a Diagnostic Tool for Celiac Disease: A Guide for Clinicians and Pathologists.,"** *Am. J. Surg. Pathol.*, Sep. 2018.
- [16] **"The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.,"** *Am. J. Surg. Pathol.*, Sep. 2018.

JAMA Oncology

- [1] **"Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma,"** *JAMA Oncol.*, Sep. 2018.
- [2] **"Assessment of the Accuracy of Disease Coding Among Patients Diagnosed With Sarcoma,"** *JAMA Oncol.*, Sep. 2018.
- [3] **"Association of *ERBB* Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma,"** *JAMA Oncol.*, Sep. 2018.
- [4] **"Association of Definitive Pelvic Radiation Therapy With Survival Among Patients With Newly Diagnosed Metastatic Cervical Cancer,"** *JAMA Oncol.*, Sep. 2018.
- [5] **"Benefits and Harms of the Centers for Medicare & Medicaid Services Ruling on Next-Generation Sequencing,"** *JAMA Oncol.*, Sep. 2018.
- [6] **"Beyond Primary Tumor Location and *RAS/BRAF* Mutational Status as Prognostic Factor in Stage III Colon Cancer,"** *JAMA Oncol.*, Sep. 2018.
- [8] **"Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies,"** *JAMA Oncol.*, Sep. 2018.
- [9] **"Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With *ERBB2/HER2* -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial,"** *JAMA Oncol.*, Mar. 2018.
- [10] **"Database Selection and Heterogeneity—More Details, More Credibility,"** *JAMA Oncol.*, Sep. 2018.
- [11] **"Disseminated Cutaneous Lesions in a Patient With a Medical History of Myelodysplastic Syndrome,"** *JAMA Oncol.*, Sep. 2018.
- [12] **"Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer,"** *JAMA Oncol.*, Sep. 2018.
- [13] **"Global Burden of Multiple Myeloma,"** *JAMA Oncol.*, Sep. 2018.
- [14] **"In Search of an Oncogene Driver for Squamous Lung Cancer,"** *JAMA Oncol.*, Sep. 2018.
- [15] **"Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density,"** *JAMA Oncol.*, Sep. 2018.
- [16] **"Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer,"** *JAMA Oncol.*, Sep. 2018.
- [17] **"Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma,"** *JAMA Oncol.*, Sep. 2018.
- [18] **"Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma,"** *JAMA Oncol.*, Aug. 2018.
- [19] **"New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics,"** *JAMA Oncol.*, Sep. 2018.
- [20] **"Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer,"** *JAMA Oncol.*, Sep. 2018.

- [21] **“Optimal Multimodal Treatment for Desmoplastic Small Round Cell Tumors,”** *JAMA Oncol.*, Sep. 2018.
- [22] **“Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial,”** *JAMA Oncol.*, Sep. 2018.
- [23] **“Paclitaxel and Pazopanib in Ovarian Cancer,”** *JAMA Oncol.*, Sep. 2018.
- [24] **“Prevalence of *PDL1* Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors,”** *JAMA Oncol.*, Sep. 2018.
- [25] **“Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma,”** *JAMA Oncol.*, Sep. 2018.
- [26] **“Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer,”** *JAMA Oncol.*, Sep. 2018.
- [27] **“Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer,”** *JAMA Oncol.*, Sep. 2018.
- [28] **“The Objective of Local Therapy in Oligometastatic Cancer Is a Moving Target,”** *JAMA Oncol.*, Sep. 2018.
- [29] **“The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk,”** *JAMA Oncol.*, Sep. 2018.
- [30] **“Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced *ERBB2/HER2* -Positive Metastatic Breast Cancer,”** *JAMA Oncol.*, Sep. 2018.



Leading the way in experimental and clinical research in hematology

- [1] **“BCL-2 inhibition in AML: an unexpected bonus?,”** *Blood*, Sep. 2018.
- [2] **“Bone marrow histopathologic findings in SIFD syndrome: beyond the erythroid lineage,”** *Blood*, Sep. 2018.
- [3] **“CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET,”** *Blood*, Sep. 2018.
- [4] **“Disparities in survival by insurance status in follicular lymphoma,”** *Blood*, Sep. 2018.
- [5] **“Insight into origins, mechanisms, and utility of DNA methylation in B-cell malignancies,”** *Blood*, Sep. 2018.
- [6] **“Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with *DUSP22* rearrangements,”** *Blood*, Sep. 2018.
- [7] **“Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma,”** *Blood*, Sep. 2018.
- [8] **“Pericardial effusion in Hodgkin lymphoma: a report from the Children’s Oncology Group AHOD0031 protocol,”** *Blood*, Sep. 2018.

MODERN PATHOLOGY

- [1] **"Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.,"** *Mod. Pathol.*, Sep. 2018.
- [2] **"Endothelial trans-differentiation in glioblastoma recurring after radiotherapy.,"** *Mod. Pathol.*, Sep. 2018.
- [3] **"Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin.,"** *Mod. Pathol.*, Sep. 2018.
- [4] **"Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.,"** *Mod. Pathol.*, Sep. 2018.
- [5] **"Intraoperatively measured tumor size and frozen section results should be considered jointly to predict the final pathology for lung adenocarcinoma.,"** *Mod. Pathol.*, Sep. 2018.
- [6] **"MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.,"** *Mod. Pathol.*, Sep. 2018.
- [7] **"Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed cases.,"** *Mod. Pathol.*, Sep. 2018.
- [8] **"Polyoma virus-associated carcinomas of the urologic tract: a clinicopathologic and molecular study.,"** *Mod. Pathol.*, Sep. 2018.
- [9] **"Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma.,"** *Mod. Pathol.*, Sep. 2018.
- [10] **"RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.,"** *Mod. Pathol.*, Sep. 2018.
- [11] **"SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.,"** *Mod. Pathol.*, Sep. 2018.
- [12] **"Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases.,"** *Mod. Pathol.*, Sep. 2018.
- [13] **"Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.,"** *Mod. Pathol.*, Sep. 2018.